View Older Stories View More Recent Stories

Oct 31, 2017 08:00AM Ethicon Showcases Leading Edge Solutions Beyond The O.R. To Empower Patients And Providers In Fight Against Obesity At ObesityWeek™ 2017
Oct 30, 2017 08:07AM Janssen (JNJ) Announces FDA Approval for New 10 mg Dosing for XARELTO to Reduce Continued Risk of VTE
Oct 30, 2017 08:00AM FDA Approves New 10 mg Dosing for XARELTO® (rivaroxaban) to Reduce the Continued Risk of Venous Thromboembolism (VTE)
Oct 25, 2017 08:23AM Janssen (JNJ) Says Darunavir-Based Single-Tablet Regimen Shows Positive Results in Previously Untreated HIV Patients in Pivotal Phase 3 AMBER Clinical Trial
Oct 25, 2017 08:04AM Investigational Darunavir-Based Single-Tablet Regimen Shows Positive Results in Previously Untreated HIV Patients in Pivotal Phase 3 AMBER Clinical Trial
Oct 23, 2017 08:15AM First General Surgery Virtual Residency Program To Allow Training Anytime, Anywhere Launched In Collaboration With Ethicon
Oct 20, 2017 04:24PM Janssen (JNJ) Receives Two U.S. FDA Approvals For SIMPONI ARIA For Treatment of Adults With Active PsA or Active Ankylosing Spondylitis
Oct 20, 2017 04:23PM Janssen Receives Two U.S. FDA Approvals For SIMPONI ARIA® (golimumab) For The Treatment Of Adults With Active Psoriatic Arthritis Or Active Ankylosing Spondylitis
Oct 16, 2017 01:32PM BabyCenter® Launches Channel On The Roku Platform To Expand Access To Best-In-Class Videos On Pregnancy And Parenthood
Oct 13, 2017 04:21PM Janssen (JNJ) Announces U.S. FDA Approval Of STELARA For The Treatment Of Adolescents With Moderate To Severe Plaque Psoriasis
Oct 13, 2017 04:20PM Janssen Announces U.S. FDA Approval Of STELARA® (ustekinumab) For The Treatment Of Adolescents With Moderate To Severe Plaque Psoriasis
Oct 11, 2017 08:45AM Janssen (JNJ) Submits U.S. NDA for Apalutamide (ARN-509) to Treat Men with Non-Metastatic Castration-Resistant Prostate Cancer
Oct 11, 2017 08:44AM Janssen Submits New Drug Application to U.S. FDA for Apalutamide (ARN-509) to Treat Men with Non-Metastatic Castration-Resistant Prostate Cancer
Oct 11, 2017 08:30AM Janssen Research & Development Establishes First-of-Its-Kind Mobile Medication and Data Management Technology Platform for Industry Use
Oct 6, 2017 02:04PM Janssen (JNJ) Says EMERALD 48-week Safety and Efficacy Results published in The Lancet HIV, to be Presented at IDWeek
Oct 6, 2017 02:02PM Janssen Announces Pivotal Phase 3 Study Results for Investigational Darunavir-Based Single-Tablet Regimen for the Treatment of HIV-1 Infection in Adults Switching from Boosted Protease Inhibitors Plus
Oct 5, 2017 04:25PM Janssen (JNJ) Says NAVIGATE ESUS Study Stopped Early Due to Futility
Oct 5, 2017 04:15PM NAVIGATE ESUS Study Stopped Early Due to Comparable Efficacy in Treatment Arms
Sep 25, 2017 08:02AM Janssen (JNJ) Submits U.S. NDA for First Darunavir-Based Single Tablet Regimen for the Treatment of HIV-1
Sep 25, 2017 08:00AM Janssen Submits New Drug Application to U.S. Food and Drug Administration for the First Darunavir-Based Single Tablet Regimen for the Treatment of HIV-1
Sep 22, 2017 04:17PM Janssen (JNJ) Receives CRL From U.S. FDA For Sirukumab Biologics License
Sep 22, 2017 04:15PM Janssen Receives Complete Response Letter From U.S. FDA For Sirukumab Biologics License Application
Sep 18, 2017 05:38AM Johnson & Johnson (JNJ) Subsidiary Janssen Research Reports New Two-Year TREMFYA (Guselkumab) Data
Sep 16, 2017 02:00AM New Two-Year TREMFYA™ (guselkumab) Data Show Patients With Moderate To Severe Plaque Psoriasis Achieved Consistent Rates Of Skin Clearance
Sep 14, 2017 04:06PM Janssen (JNJ) Submits sNDA to FDA for ZYTIGA to Treat Men with Earlier Stages of Metastatic Prostate Cancer
Sep 14, 2017 04:03PM Janssen Submits Supplemental New Drug Application to U.S. FDA for ZYTIGA® (abiraterone acetate) to Treat Men with Earlier Stages of Metastatic Prostate Cancer
Aug 31, 2017 08:05AM Multiple Myeloma Patients and Supporters Embark on Cross-Country Journey to Raise Awareness and Accelerate Cancer Research
Aug 30, 2017 09:00AM Ethicon Reports Major Progress On Multi-Year Initiative To Fill Clinical And Economic Evidence Gaps And Expand Access To Bariatric Surgery
Aug 21, 2017 08:15AM Ethicon Launches ProxiSure™ Suturing Device Designed To Improve Precision In Minimally-Invasive Surgery
Aug 16, 2017 01:22PM President Trump Announces End of Strategic & Policy Forum and Manufacturing Council on Twitter
Aug 2, 2017 05:06PM Janssen (JNJ) Confirms FDA Advisory Committee Does Not Recommend Approval of Sirukumab to Treat RA
Aug 2, 2017 04:49PM FDA Advisory Committee Does Not Recommend Approval Of Sirukumab For The Treatment Of Moderately To Severely Active Rheumatoid Arthritis
Aug 2, 2017 01:35PM Johnson & Johnson (JNJ) Announces FDA Approval for IMBRUVICA in Adults with cGVHD
Aug 2, 2017 01:32PM U.S. FDA Approves IMBRUVICA® (ibrutinib) as First and Only Approved Treatment for Adult Patients with Chronic Graft-Versus-Host-Disease (cGVHD) After Failure of One or More Lines of Systemic Therapy
Jul 13, 2017 04:12PM Johnson & Johnson (JNJ) Janssen Gains FDA Approval for Plaque Psoriasis Treatment TREMFYA
Jul 13, 2017 04:10PM Janssen Announces U.S. FDA Approval Of TREMFYA™ (Guselkumab) For The Treatment Of Moderate To Severe Plaque Psoriasis
Jul 11, 2017 03:29PM Endangered Baby Names 2017
Jun 22, 2017 08:04AM Johnson & Johnson Releases 2016 Health for Humanity Report
Jun 16, 2017 02:18PM Janssen Biotech (JNJ) Granted FDA Approval for DARZALEX (daratumumab) in Combination with Pomalidomide & Dexamethasone
Jun 16, 2017 02:15PM DARZALEX® (daratumumab) Approved by the U.S. FDA in Combination with Pomalidomide and Dexamethasone for Patients with Multiple Myeloma Who Have Received At Least Two Prior Therapies
Jun 16, 2017 06:14AM Johnson & Johnson (JNJ) Completes Acquisition of Actelion
Jun 16, 2017 01:00AM Johnson & Johnson Announces Completion of Acquisition of Actelion
Jun 9, 2017 11:30AM Johnson & Johnson Announces Expected Settlement of Actelion Tender Offer on June 16, 2017
Jun 6, 2017 08:32AM Johnson & Johnson (JNJ) Subsidiary, Ethicon Granted FDA Approval for SURGICEL Powder Absorbable Hemostat
Jun 6, 2017 08:30AM Ethicon Announces FDA Approval For SURGICEL Powder Absorbable Hemostat
Jun 5, 2017 07:23AM Janssen (JNJ) Announces Daratumumab Combination Therapy Improved Clinical Outcomes Regardless of Cytogenetic Risk for Previously-Treated Patients with Multiple Myeloma
Jun 5, 2017 07:21AM Janssen (JNJ) Reports Abiraterone Acetate Provided Significant Clinical Benefit in Patients with High-Risk Metastatic Hormone-Naive Prostate Cancer (mHNPC)
Jun 5, 2017 07:10AM Janssen (JNJ) Says Data at ASCO Show Consistent Progression-Free Survival Benefit in R/R CLL/SLL Patients Treated with Ibrutinib
Jun 5, 2017 07:05AM Data at ASCO Show Consistent Progression-Free Survival Benefit in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Patients Treated with Ibrutinib, Including Those with High
Jun 4, 2017 10:56AM Daratumumab Combination Therapy Improved Clinical Outcomes Regardless of Cytogenetic Risk for Previously-Treated Patients with Multiple Myeloma
View More Recent Stories View Older Stories